Malta - English - Medicines Authority

accord healthcare limited - idarubicin hydrochloride - solution for injection - idarubicin hydrochloride 5 mg/ml - antineoplastic agents

Malta - English - Medicines Authority

accord healthcare limited - idarubicin hydrochloride - solution for injection - idarubicin hydrochloride 1 mg/ml - antineoplastic agents

United States - English - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - doxorubicin hydrochloride (unii: 82f2g7bl4e) (doxorubicin - unii:80168379ag) - - cardiomyopathy: myocardial damage, including acute left ventricular failure can occur with doxorubicin. the risk of cardiomyopathy is proportional to the cumulative exposure with incidences from 1% to 20% for cumulative doses from 300 mg/m2 to 500 mg/m2 when doxorubicin is administered every 3 weeks. the risk of cardiomyopathy is further increased with concomitant cardiotoxic therapy. assess lvef before and regularly during and after treatment with doxorubicin [see warnings and precautions (5.1)]. - secondary malignancies: secondary acute myelogenous leukemia (aml) and myelodysplastic syndrome (mds) occur at a higher incidence in patients treated with anthracyclines, including doxorubicin [see warnings and precautions (5.2)]. extravasation and tissue necrosis: extravasation of doxorubicin can result in severe local tissue injury and necrosis requiring wide excision of the affected area and skin grafting.immediately terminate the drug, and apply ice to the affected area [see warnings and precautions (5.

Malta - English - Medicines Authority

accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - idarubicin hydrochloride - solution for injection - idarubicin hydrochloride 1 mg/ml - antineoplastic agents

Malta - English - Medicines Authority

accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - idarubicin hydrochloride - solution for injection - idarubicin hydrochloride 1 mg/ml - antineoplastic agents

Malta - English - Medicines Authority

accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - idarubicin hydrochloride - solution for injection - idarubicin hydrochloride 1 mg/ml - antineoplastic agents

Ireland - English - HPRA (Health Products Regulatory Authority)

novartis pharmaceuticals uk ltd - dexrazoxane - pdr/conc/soln for infus - 500mg/vial milligram

Israel - English - Ministry of Health

abic marketing ltd, israel - doxorubicin hydrochloride - concentrate for solution for infusion - doxorubicin hydrochloride 2 mg/ml - doxorubicin - doxorubicin - to produce regression in disseminated neoplastic conditions such as: - acute lymphoblastic leukemia, - acute myeloblastic leukemia, - wilms' tumor neuroblastoma, - soft tissue and bone sarcomas, - breast carcinoma, - lymphomas of both hodgkin's and non-hodgkin's types, - bronchogenic carcinoma in which the small cell histologic type is the most responsive compared to other cell types, - gastric carcinoma.

Israel - English - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - idarubicin hydrochloride - powder for concentrate for solution for infusion - idarubicin hydrochloride 10 mg/vial - idarubicin - idarubicin - antimitotic and cytotoxic agent. acute non-limphocytic leukemia (anll) in adults for remission induction in untreated patients or for remission induction in relapsed or refractory patients.acute limphocytic leukemia (all) as second line treatment in adults and children.

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare limited - doxorubicin hydrochloride - concentrate for soln for inf - 2 mg/ml - doxorubicin